The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Axi-cel as second-line therapy for R/R large B-cell lymphoma
Axicabtagene ciloleucel (axi-cel), an autologous anti‑CD19 chimeric antigen receptor (CAR) T-cell therapy, is currently only approved for third-line therapy in large B-cell lymphoma (LBCL). Jason Westin, MD, FACP, University of Texas MD Anderson Center, Houston, TX, comments on data from the Phase III ZUMA-7 trial (NCT03391466) which assessed axi-cel in patients with relapsed/refractory (r/r) LBCL. The primary endpoint, event-free survival (EFS), was met after a 24 month follow-up, suggesting that axi-cel should be moved to second-line therapy as the standard of care. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
